Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

被引：0

作者：

Mathew Vithayathil

Antonio D’Alessio

Claudia Angela Maria Fulgenzi

Naoshi Nishida

Martin Schönlein

Johann von Felden

Kornelius Schulze

Henning Wege

Anwaar Saeed

Brooke Wietharn

Hannah Hildebrand

Linda Wu

Celina Ang

Thomas U. Marron

Arndt Weinmann

Peter R. Galle

Dominik Bettinger

Bertram Bengsch

Arndt Vogel

Lorenz Balcar

Bernhard Scheiner

Pei-Chang Lee

Yi-Hsiang Huang

Suneetha Amara

Mahvish Muzaffar

Abdul Rafeh Naqash

Antonella Cammarota

Valentina Zanuso

Tiziana Pressiani

Matthias Pinter

Alessio Cortellini

Masatoshi Kudo

Lorenza Rimassa

David J. Pinato

Rohini Sharma

机构：

[1] Imperial College London,Department of Surgery & Cancer

[2] Hammersmith Campus,Department of Biomedical Sciences

[3] Humanitas University,Division of Medical Oncology

[4] Policlinico Universitario Campus Bio-Medico,Department of Gastroenterology and Hepatology, Faculty of Medicine

[5] Kindai University,Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology

[6] University Medical Center Hamburg-Eppendorf,Department of Gastroenterology and Hepatology

[7] University Medical Center Hamburg-Eppendorf,Division of Medical Oncology, Department of Medicine

[8] Kansas University Cancer Center,Division of Hematology/Oncology, Department of Medicine

[9] Tisch Cancer Institute,I. Medical Department

[10] Mount Sinai Hospital,Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine

[11] University Medical Center Mainz,Division of Gastroenterology & Hepatology, Department of Internal Medicine III

[12] Freiburg University Medical Center,Division of Gastroenterology and Hepatology, Department of Medicine

[13] University of Freiburg,Institute of Clinical Medicine, School of Medicine

[14] University of Freiburg,Division of Hematology/Oncology

[15] Signalling Research Centers BIOSS and CIBSS,Medical Oncology and Hematology Unit

[16] German Cancer Consortium (DKTK),Division of Oncology, Department of Translational Medicine

[17] Hannover Medical School,undefined

[18] Medical University of Vienna,undefined

[19] Taipei Veterans General Hospital,undefined

[20] National Yang Ming Chiao Tung University,undefined

[21] East Carolina University,undefined

[22] Medical Oncology/TSET Phase 1 Program,undefined

[23] Stephenson Cancer Center,undefined

[24] University of Oklahoma,undefined

[25] Humanitas Cancer Center,undefined

[26] IRCCS Humanitas Research Hospital,undefined

[27] University of Piemonte Orientale,undefined

来源：

Hepatology International | 2023年 / 17卷

关键词：

Immunotherapy; Anti-programmed death-ligand; Anti-vascular endothelial growth factor; Checkpoint inhibitor; Obesity; Cirrhosis; Overall survival; Progression-free survival; Overweight; Non-alcoholic fatty liver disease;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：904 / 914

页数：10

共 468 条

[1]

Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2]

Ferlay J(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390

[3]

Soerjomataram I(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet (London, England) 391 1163-1173

[4]

Siegel RL(2021)Immunotherapy in hepatocellular carcinoma Curr Treat Options Oncol 22 87-1905

[5]

Torre LA(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 382 1894-873

[6]

Jemal A(2022)Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma J Hepatol 76 862-379

[7]

Llovet JM(2022)Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA J Clin Oncol 40 379-248

[8]

Ricci S(2021)Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis Liver cancer 10 240-1558

[9]

Mazzaferro V(2017)Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI Oncotarget 8 72959-908

[10]

Hilgard P(2021)Body size and composition and risk of site-specific cancers in the UK Biobank and large international consortia: a mendelian randomisation study PLoS Med 18 e1003706-42

← 1 2 3 4 5 6 7 8 9 10 →